You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
AstraZeneca
Colorcon
McKesson
Harvard Business School

Last Updated: October 2, 2023

Actelion Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Actelion
International Patents:246
US Patents:15
Tradenames:6
Ingredients:6
NDAs:8
PTAB Cases with Actelion as petitioner: See PTAB cases with Actelion as petitioner

Drugs and US Patents for Actelion

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion UPTRAVI selexipag TABLET;ORAL 207947-003 Dec 21, 2015 RX Yes No 8,791,122 ⤷  Try a Trial Y Y ⤷  Try a Trial
Actelion UPTRAVI selexipag TABLET;ORAL 207947-005 Dec 21, 2015 RX Yes No 9,284,280 ⤷  Try a Trial ⤷  Try a Trial
Actelion VENTAVIS iloprost SOLUTION;INHALATION 021779-003 Aug 7, 2009 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Actelion

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Actelion ZAVESCA miglustat CAPSULE;ORAL 021348-001 Jul 31, 2003 5,472,969 ⤷  Try a Trial
Actelion TRACLEER bosentan TABLET;ORAL 021290-002 Nov 20, 2001 5,292,740 ⤷  Try a Trial
Actelion TRACLEER bosentan TABLET;ORAL 021290-001 Nov 20, 2001 5,292,740 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ACTELION drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 10 mg ➤ Subscribe 2017-10-18
➤ Subscribe for Oral Suspension 32 mg ➤ Subscribe 2019-02-08

Supplementary Protection Certificates for Actelion Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1345920 300672 Netherlands ⤷  Try a Trial PRODUCT NAME: MACITENTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/893/001-003 20131220
1345920 CR 2014 00012 Denmark ⤷  Try a Trial PRODUCT NAME: MACITENTAN OG FARMACEUTISK ACCEPTABLE SALTE HERAF; REG. NO/DATE: EU/1/13/893 20131227
1400518 122016000077 Germany ⤷  Try a Trial PRODUCT NAME: SELEXIPAG ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083/001-010 20160512
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Mallinckrodt
Colorcon
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.